Immunoassay News and Research

RSS

FDA clears innovative blood test for earlier Alzheimer's diagnosis

The U.S. Food and Drug Administration (FDA) has cleared for marketing an innovative blood test with underlying technology invented at Washington University School of Medicine in St. Louis for the early diagnosis of Alzheimer's disease.

21 Aug 2026

Researchers develop noninvasive chairside test to detect oral cancer

A Case Western Reserve University–led research team is developing a noninvasive oral cancer test to help clinicians decide-chairside and within minutes- whether a suspicious lesion in the mouth needs a biopsy.

12 Aug 2026

New multi-protein blood test accurately detects late-stage Alzheimer's disease

Researchers have identified seven proteins in the blood that could enable better blood tests for Alzheimer's disease.

11 Aug 2026

New portable strip test accurately detects mosquito-borne viruses

A research team has developed a multisite bridging-mediated lateral flow immunoassay (mbLFIA) that enables highly sensitive, portable detection of mosquito-borne viruses, using Chikungunya virus (CHIKV) as a model target.

17 Jul 2026

G&H highlights end-to-end diagnostic device development at ADLM 2026

At the ADLM Clinical Lab Expo 2026, G&H will showcase how diagnostic and medical device companies can accelerate the development and commercialization of innovative healthcare technologies through a single partner offering multidisciplinary engineering, precision optics, photonics and ISO 13485-certified manufacturing.

17 Jul 2026

Spear Bio to unveil novel Alzheimer’s disease immunoassays and fully automated instrument platform at AAIC 2026

Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced plans to unveil new SPEAR immunoassay and instrument innovations at the Alzheimer’s Association International Conference® 2026, taking place July 12–15 in London, UK.

From Spear Bio 9 Jul 2026

Direct-to-definitive toxicology screening: Moving beyond immunoassays in clinical toxicology

Discover expert insights into toxicology screening with mass spectrometry, reducing false results and improving patient safety in clinical toxicology.

From Waters Advanced Diagnostics 9 Jul 2026

Beckman Coulter Diagnostics expands Alzheimer’s portfolio with CE-marked p-Tau217 blood test and new high-specificity research assay

Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline.

7 Jul 2026

Merck KGaA, Darmstadt, Germany, agrees to acquire Bio-Techne, strengthening leadership position in fast-growing life sciences markets

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price.

From Bio-Techne 25 Jun 2026

How exercise influences cancer cell viability

This interview uncovers how exercise may reduce cancer cell viability, with insights into adipose interactions and innovative 3D culture systems.

From Promega Corporation 15 May 2026

Could a fingerprick at home flag your Alzheimer's risk? New study says yes

Researchers demonstrated that self-administered fingerprick blood tests measuring p-tau217 and GFAP, returned by post, correlate strongly with venous blood biomarkers and cognitive performance across the Alzheimer's disease continuum. Combined with computerized cognitive testing, this at-home approach offers a scalable, patient-friendly tool for triaging individuals at risk of AD-related impairment.

10 May 2026

Hantavirus scare on cruise ship prompts WHO response

Hantavirus infections among cruise ship passengers have sparked a global health response, highlighting the need for effective outbreak management strategies.

7 May 2026

CDC HoSt-TT certification for Siemens Healthineers total testosterone test expands patient access to gold standard equivalent results

Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT).

From Siemens Healthineers 5 May 2026

Beckman Coulter Diagnostics earns CE mark for new assay delivering bacterial vs viral infection results in approximately 20 minutes

Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.

From Beckman Coulter Diagnostics 13 Apr 2026

Researchers develop DNA aptamer to detect Alzheimer's biomarkers

With aging populations on the rise, the need for better tools to diagnose and monitor Alzheimer's disease (AD), the most common cause of dementia, has never been more urgent.

10 Mar 2026

Nearly 70 weeks after infection, long COVID patients show no detectable inflammation in blood tests

A controlled Norwegian case-control study examined circulating biomarkers of inflammation and neuronal injury in people with long COVID about 69 weeks after infection. The researchers found no significant differences in systemic inflammatory or neuroinjury markers compared with recovered controls after statistical correction.

4 Mar 2026

Blood test models predict when Alzheimer’s symptoms may start years in advance

Researchers developed plasma p-tau217–based clock models that estimate when cognitively unimpaired individuals with Alzheimer’s pathology may develop symptomatic disease. The models predicted symptom onset within about three to four years and may help improve clinical trial selection while remaining unsuitable for individual clinical decisions at present.

22 Feb 2026

New at-home tests accurately detect deadly pet parvoviruses

Pet owners want quick answers when their beloved cat or dog is sick. And if these furry friends are experiencing digestive distress, lethargy and fever, it's important to rapidly rule out serious illnesses like feline panleukopenia (also called feline parvovirus) and canine parvovirus.

10 Feb 2026

Global Alzheimer’s Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study.

From Spear Bio 18 Jan 2026

Formulatrix® and Spear Bio advance automated ultrasensitive protein detection through ongoing partnership

Formulatrix, a leader in laboratory automation solutions, and Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced their ongoing partnership to automate and optimize the SPEAR UltraDetect™ assay platform using the F.A.S.T.™ (Flow Axial Seal Tip) Liquid Handler.

From Spear Bio 15 Jan 2026